Drug Profile
Docetaxel - CLL PHARMA
Alternative Names: SYN 2004Latest Information Update: 18 Dec 2021
Price :
$50
*
At a glance
- Originator CLL PHARMA
- Class Antineoplastics; Radiopharmaceutical diagnostics; Small molecules; Taxanes
- Mechanism of Action Mitosis inhibitors; Tubulin modulators; Tubulin polymerisation promoters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Jun 2020 No recent reports of development identified for preclinical development in Cancer in France
- 01 Jun 2016 Chemical structure information added
- 31 May 2016 Preclinical trials in Cancer in France (unspecified route) before May 2016